Compare RGLD & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGLD | JAZZ |
|---|---|---|
| Founded | 1981 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6B | 15.0B |
| IPO Year | 1995 | 2007 |
| Metric | RGLD | JAZZ |
|---|---|---|
| Price | $221.62 | $227.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 14 |
| Target Price | ★ $262.17 | $217.57 |
| AVG Volume (30 Days) | 627.1K | ★ 798.0K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | ★ 32.74 | N/A |
| EPS | 3.30 | ★ 4.43 |
| Revenue | $1,030,471,000.00 | ★ $1,618,693,000.00 |
| Revenue This Year | $89.85 | $6.22 |
| Revenue Next Year | $5.05 | $7.68 |
| P/E Ratio | $65.31 | ★ $52.05 |
| Revenue Growth | ★ 43.24 | N/A |
| 52 Week Low | $150.75 | $105.00 |
| 52 Week High | $306.25 | $243.32 |
| Indicator | RGLD | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 50.32 | 47.39 |
| Support Level | $214.71 | $224.23 |
| Resistance Level | $231.83 | $242.66 |
| Average True Range (ATR) | 6.92 | 7.08 |
| MACD | 1.26 | -2.00 |
| Stochastic Oscillator | 77.03 | 10.42 |
Royal Gold Inc enquires and manages precious metal royalties and streams with a focus on gold. The company purchases a percentage of the metal produced from a mineral property for an initial payment without assuming responsibility for mining operations. Similarly, precious metal streams are purchase agreements with mine operators providing the right to purchase all or a portion of one or more metals produced from a mine in exchange for an upfront deposit payment. Generally, Royal Gold does not work on the properties in which it holds royalty and streaming assets. The company owns a portfolio of producing, development, evaluation, and exploration royalties and streams, and the majority of group revenue is generated from Canada, Mexico, Chile, and the United States.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.